Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of BMS-626529
NCT02805556Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Mar 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fostemsavir in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoint: Absolute bioavailability of BMS-626529 up to 11 days. Started Mar 2016; status: completed.
02
Drugs
fostemsavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02805556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02805556.